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lel sample (n = 137) the average quarterly costs had increased by
13% (ns). CONCLUSIONS: Computerised data collection per-
formed by the doctor provide detailed information about diag-
nosis, treatments, and referrals making possible the study of
patient pathways and costs. DPMA is cost-effective in provision
of care.
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OBJECTIVES: Comparison of annual medication costs in a 
population-based study using a prediction formula based on 7
day medication history to cost data provided by health insurance
companies. METHODS: The KORA Asthma and Allergy 
study evaluated cost of illness due to asthma and allergies in a
population-based case-control design. Medication costs origi-
nated from a 7 day medication history (interview) and from
health insurance data. Drugs documented per interview were
assigned an average price per deﬁned daily dose (DDD) for each
standard package size group. Weekly medication costs were
extrapolated by multiplying price per DDD (medium package
size) by predicted length of intake according to general ATC
group. For consenting subjects, all medications reimbursed by
the health insurance companies for 1998 were obtained. The
annual total costs as well as cost differences between disease
groups were compared between both approaches. RESULTS: Of
1534 subjects participating in the KORA study, 1249 were
insured publicly and 63.8% of those consented to release their
health insurance data. Of 614 persons with prescribed medica-
tions according to insurance data, 233 (38%) reported no pre-
scribed medications during the interview. Median (inter-quartile
range) annual costs for this group were 37€ (16–103€). For the
other 381 subjects (62%), annual insurance costs were 260€
(116–638€) whereas predicted costs were higher (364€; 104–
863€). For subjects with asthma or allergy, predicted costs agreed
better with annual costs. Costs extrapolated from interview data
correlated signiﬁcantly (r = 0.63) with the annual costs. CON-
CLUSIONS: Estimation of annual medication costs for chronic
disease patients from seven day medication history data is feasi-
ble and estimates of group averages are similar to full annual
data from health insurance companies. For population-based
samples the latter approach is logistically more difﬁcult, is less
accepted by subjects, and does not encompass costs of most of
OTC drugs.
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OBJECTIVES: Estimating costs for different pharmaceutical
treatments based on data from clinical studies with discontinu-
ation is a problem with no general solution. Especially early dis-
continuations are often correlated with high initial costs, which
may have large impact on the estimates. A number of approaches
suggested in the literature for dealing with this problem were
investigated using data from clinical studies in the respiratory
ﬁeld to see if a consistent pattern could be found. METHODS:
Data from three large clinical studies (two concerning asthma,
one concerning COPD) were investigated for three different
approaches: PYA, Patient-Year Approach (linear extrapolation
for each patient to nominal duration of study), GMI, Group
Mean Imputation where missing data for a certain period is
replaced by the relevant group mean for corresponding period,
and GSA, Group-Sum Approach where data are summed over
treatment groups, implying that data are weighted according to
time in study for each patient. While the ﬁrst two approaches
are based on individual data and variation in estimates are easily
found by standard methods, precision in GSA estimates is found
by non-parametric bootstrapping. RESULTS: Data show that
discontinuations, and especially early discontinuations due to
exacerbations followed by intensive treatment, can have a sub-
stantial impact on the PYA approach, where the estimated mean
cost can be twice as high compared to the other approaches.
Demanding a certain time in study as qualifying for inclusion in
the analysis will gradually bring the results in agreement with
the GMI and GSA approach. CONCLUSIONS: In large clinical
studies, the GMI approach may be inconvenient because of
varying periods. The GSA approach in combination with non-
parametric bootstrapping for ﬁnding precision in estimates is a
simple and robust method.
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OBJECTIVES: To investigate if the results of four published
algorithms for calculating utility values from assessments of SF-
36 are in agreement with the responses of traditional efﬁcacy
variables assessed in clinical studies in the respiratory ﬁeld.
METHODS: Data from six different randomized clinical studies,
two from each of the disease areas of asthma, rhinitis and COPD,
comparing two treatments, are used in the investigation. Base-
line values before randomizing to study treatment are compared
for the algorithms as well as change during treatment. Change
during treatment is compared to the primary efﬁcacy variable in
each study. RESULTS: Mean utility values at baseline show a
consistent pattern across disease areas with large individual vari-
ation, with utility values ranging from 0.28 to 0.99 and with
mean values ranging from 0.58 to 0.82. Change during treat-
ment is small (0.00 to 0.11) and in most cases statistically non-
signiﬁcant when comparing treatments. Correlation with clinical
efﬁcacy is of moderate magnitude. CONCLUSION: The two
utility measures based on Standard Gamble or TTO seems to be
slightly better than those based on VAS or linear regression. The
pattern across the different disease areas is consistent for the dif-
ferent algorithms.
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